



SAFETY DATA SHEET

Revision date: 14-May-2015

Version: 2.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: CORTEF (Hydrocortisone) Tablets

Trade Name: CORTEF; CORTRIL
Synonyms: Hydrocortisone Tablets
Chemical Family: Glucocorticoid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anti-inflammatory

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Warning
Hazard Statements: H361d - Suspected of damaging the unborn child

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 2 of 10
Version: 2.0



Other Hazards

Australian Hazard Classification (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Hydrocortisone	50-23-7	200-020-1	Repr.Cat.3;R63	Repr. 2 (H361d)	4
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*
Mineral oil	8012-95-1	232-384-2	Not Listed	Not Listed	*
Calcium stearate	1592-23-0	216-472-8	Not Listed	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sorbic acid	110-44-1	203-768-7	Not Listed	Not Listed	*
Lactose Monohydrate	64044-51-5	Not Listed	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 3 of 10
Version: 2.0

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
 Revision date: 14-May-2015

Page 4 of 10
 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Hydrocortisone

Pfizer OEL TWA-8 Hr: 100 µg/m³, Skin

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Mineral oil

ACGIH Threshold Limit Value (TWA)	5 mg/m ³
Australia TWA	5 mg/m ³
Belgium OEL - TWA	5 mg/m ³
Bulgaria OEL - TWA	5.0 mg/m ³
Czech Republic OEL - TWA	5 mg/m ³
Denmark OEL - TWA	1 mg/m ³
Finland OEL - TWA	5 mg/m ³
Greece OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	1 mg/m ³
Netherlands OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	5 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 mg/m ³
Romania OEL - TWA	5 mg/m ³
Slovakia OEL - TWA	5 ppm
	1 mg/m ³
	5 mg/m ³
Spain OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Calcium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 5 of 10
Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	White
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	
Mineral oil	No data available
Sorbic acid	No data available
Calcium stearate	No data available
Corn Starch	No data available
Sucrose	No data available
Lactose Monohydrate	No data available
Hydrocortisone	
Predicted 7.4 Log D 1.43	
Decomposition Temperature (°C):	No data available.

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 6 of 10
Version: 2.0

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable at normal conditions
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause minimal eye irritation (based on animal data). May be harmful if swallowed. May be harmful if absorbed through the skin. (based on components) . Accidental ingestion may cause effects similar to those seen in clinical use.

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, muscle cramps, weakness, nervousness, restlessness, trouble sleeping
Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. Clinical use may cause an increase in blood pressure (hypertension).

Acute Toxicity: (Species, Route, End Point, Dose)

Sorbic acid

Rat Oral LD50 7360 mg/kg
Mouse Oral LD50 3200mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 7 of 10
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Hydrocortisone

Rat Oral LD 50 5000 mg/kg
Mouse Oral LD 50 5000mg/kg
Rat Subcutaneous LD 50 449mg/kg
Rat Intraperitoneal LD 50 150mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Mineral oil

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Hydrocortisone

Eye Irritation Rabbit Minimal

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Hydrocortisone

7 Day(s) Mouse Oral 140 mg/kg/day LOAEL Thymus
4 Day(s) Mouse Subcutaneous 100 mg/kg/day LOAEL Liver
2 Week(s) Mouse Subcutaneous 560 mg/kg/day LOAEL Liver, Bone Marrow
85 Day(s) Rat Subcutaneous 175 mg/kg/day LOAEL Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Hydrocortisone

Embryo / Fetal Development Mouse Oral 10 mg/kg/day LOAEL Teratogenic
Reproductive & Fertility Rat Oral 210 mg/kg/day LOAEL Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

Hydrocortisone

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Unscheduled DNA Synthesis Rat Negative

Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:

No data available

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 8 of 10
Version: 2.0

Persistence and Degradability: No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Hydrocortisone

Predicted 7.4 Log D 1.43

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Hydrocortisone

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
 Revision date: 14-May-2015

Page 9 of 10
 Version: 2.0

15. REGULATORY INFORMATION

Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 3 Schedule 4
EU EINECS/ELINCS List	200-020-1
Corn Starch	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6
Sorbic acid	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-768-7
Lactose Monohydrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	Not Listed
Mineral oil	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-384-2
Calcium stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	216-472-8
Sucrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

SAFETY DATA SHEET

Material Name: CORTEF (Hydrocortisone) Tablets
Revision date: 14-May-2015

Page 10 of 10
Version: 2.0

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Xn - Harmful

R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 14-May-2015
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet